Thermo Fisher (TMO) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Thermo Fisher Scientific reported revenue of $10.54 billion for the quarter ended June 2024, reflecting a year-over-year decline of 1.4% [5] - The reported EPS was $5.37, an increase from $5.15 a year ago, indicating a positive surprise of +4.68% over the consensus estimate of $5.13 [1][5] Revenue Breakdown - Organic revenue growth was -1%, slightly better than the average estimate of -1.6% [3] - Laboratory Products and Biopharma Services generated $5.76 billion, exceeding the average estimate of $5.75 billion, with a year-over-year change of -1.3% [3] - Specialty Diagnostics revenue was $1.12 billion, surpassing the average estimate of $1.10 billion, showing a year-over-year increase of +0.7% [3] - Life Sciences Solutions reported revenues of $2.36 billion, matching the average estimate but reflecting a year-over-year decline of -4.4% [3] - Eliminations accounted for -$470 million, slightly worse than the average estimate of -$453.83 million, but showing a year-over-year improvement of +1.1% [3] - Analytical Instruments revenue was $1.78 billion, slightly above the average estimate of $1.77 billion, with a year-over-year increase of +1.9% [3] Stock Performance - Over the past month, Thermo Fisher shares returned -0.8%, underperforming compared to the Zacks S&P 500 composite's +1.8% change [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]